publication date: Feb. 14, 2020

Clinical Roundup

City of Hope Triplex vaccine reduces rate of CMV complications in transplant recipients by half

Patients who underwent a stem cell transplant and received the Triplex vaccine to prevent a type of herpes virus, cytomegalovirus, from duplicating out of control were 50% less likely to develop health complications related to the virus than patients who did not take Triplex, according to a City of Hope-led study published today in Annals of Internal Medicine.

The phase II randomized, placebo-controlled clinical trial, which took place at City of Hope, Dana-Farber Cancer Institute and MD Anderson Cancer Center, is the first time a viral anti-CMV vaccine has been tested in patients. The trial enrolled 102 patients who underwent an allogeneic hematopoietic stem cell transplant.

Half of the patients were randomly assigned to receive Triplex, developed by City of Hope scientists to enhance CMV-specific T cells, create immunity in patients against CMV and prevent it from causing such severe complications as pneumonia, gastroenteritis and retinitis.

In the trial, patients who received at least the first of two planned injections of Triplex on day 28 and day 56 after HSCT had 50% fewer CMV complications (virus reactivation, antiviral treatment and disease) through day 100 (primary endpoint) than those who received the placebo. There were five subjects with CMV complications in the vaccine arm versus 10 in the placebo arm.

In addition, patients who received Triplex developed immunity against CMV that was 197% higher than those in the placebo group. Prior to undergoing a transplant, patients received high-dose chemotherapy to obliterate the hematopoietic system, which produces blood and is part of the immune system. Despite having weakened immune systems, patients who received Triplex developed immunity … Continue reading City of Hope Triplex vaccine reduces rate of CMV complications in transplant recipients by half

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.